A study conducted by Dr. Mark Ware of the McGill University Health Center and McGill University in Montreal finds that medical marijuana relieves chronic neuropathic pain.
The study, published in the Canadian Medical Association Journal, concluded that a single inhalation of 25 mg of 9.4% tetrahydrocannabinol herbal cannabis three times daily for five days reduced the intensity of pain, improved sleep and was well tolerated.
The study was conducted on men and women aged 18 years or older with neuropathic pain of at least three months in duration caused by trauma or surgery, and it is the first double-blind, placebo-controlled trial conducted with outpatients who were allowed to smoke marijuana in their own homes.
While this is huge news for the multi-billion dollar chronic neuropathic pain market, it’s old news to thousands of medical marijuana patients and supporters who already know about medical marijuana and chronic pain. Cannabis Science President and CEO Dr. Robert Melamede, PhD., put it best when he commented, ” As Dr. Ware said at the beginning of the CMAJ article, cannabis sativa has been used to treat pain since the third millennium BC, so it is all the more outrageous that it has taken so long for such a study to be done, and it could only be used by patients who did not respond to anything else. Why do they have to suffer so much to prove what almost all medical marijuana users already know?”
But the larger value here is that we are actually seeing a medical marijuana study on real patients, which is hindered by federal laws in the United States. Hopefully we’ll be seeing more scientific studies like this which will surely help more people finally accept that medical marijuana is a powerful medicine.
You can read the entire study here.